$TLCC
Twinlab Consolidated Holdings Inc Stock $tlcc

$tlcc Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000175392621000710 Filed on November 15, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q3
Revenue	$16.25M	$18.27M	$18.37M
YoY Change	-15.97%	-0.54%	-7.46%
Cost Of Revenue	$17.67M	$12.23M	$14.67M
YoY Change	-12.31%	-16.63%	-19.35%
Gross Profit	-$1.419M	$6.042M	$3.702M
YoY Change	74.97%	63.21%	122.61%
Gross Profit Margin	-8.73%	33.07%	20.15%
Selling, General & Admin	$1.547M	$5.008M	$3.401M
YoY Change	-42.19%	47.25%	-38.14%
% of Gross Profit		82.89%	91.87%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$106.0K	$55.00K	$9.000K
YoY Change	-61.73%	511.11%	125.0%
% of Gross Profit		0.91%	0.24%
Operating Expenses	$1.547M	$5.008M	$3.401M
YoY Change	-42.19%	47.25%	-38.14%
Operating Profit	-$2.966M	$1.034M	$301.0K
YoY Change	-14.94%	243.52%	-107.85%
Interest Expense	-$1.992M	$2.208M	$2.183M
YoY Change	-19.19%	1.15%	1.35%
% of Operating Profit		213.54%	725.25%
Other Income/Expense, Net	$872.0K	-$2.222M	-$2.153M
YoY Change	-4252.38%	3.2%	-447.82%
Pretax Income	-$15.20M	-$1.188M	-$1.852M
YoY Change	154.55%	-35.85%	-42.41%
Income Tax	$13.00K	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$15.22M	-$1.188M	-$1.852M
YoY Change	153.15%	-35.85%	-42.41%
Net Earnings / Revenue	-93.65%	-6.5%	-10.08%
Basic Earnings Per Share		$0.00	-$0.01
Diluted Earnings Per Share	-$58.73K	$0.00	-$0.01
COMMON SHARES
Basic Shares Outstanding	259.1M shares	259.1M shares	258.1M shares
Diluted Shares Outstanding		259.1M shares	259.1M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.631M	$2.148M	$877.0K
YoY Change	756.37%	144.93%	-57.94%
Cash & Equivalents	$3.631M	$2.148M	$877.0K
Short-Term Investments
Other Short-Term Assets	$1.045M	$2.067M	$3.627M
YoY Change	-52.39%	-43.01%	-29.87%
Inventory	$5.814M	$10.57M	$8.234M
Prepaid Expenses			$3.627M
Receivables	$6.881M	$10.40M	$5.654M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$17.37M	$25.19M	$18.39M
YoY Change	0.15%	36.93%	-18.68%
LONG-TERM ASSETS
Property, Plant & Equipment	$140.0K	$143.0K	$64.00K
YoY Change	115.38%	123.44%	-88.53%
Goodwill	$0.00	$8.818M	$8.818M
YoY Change	-100.0%	0.0%	-50.45%
Intangibles	$576.0K	$2.970M	$3.531M
YoY Change	-82.29%	-15.89%	-82.49%
Long-Term Investments
YoY Change
Other Assets	$1.301M	$1.713M	$778.0K
YoY Change	71.18%	120.18%	-59.35%
Total Long-Term Assets	$7.497M	$19.49M	$18.11M
YoY Change	-57.42%	7.64%	-55.23%
TOTAL ASSETS
Total Short-Term Assets	$17.37M	$25.19M	$18.39M
Total Long-Term Assets	$7.497M	$19.49M	$18.11M
Total Assets	$24.87M	$44.68M	$36.50M
YoY Change	-28.85%	22.4%	-42.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.047M	$4.612M	$2.870M
YoY Change	28.33%	60.7%	-65.57%
Accrued Expenses	$31.15M	$31.24M	$23.72M
YoY Change	17.36%	31.69%	25.12%
Deferred Revenue	$2.160M	$4.660M	$4.297M
YoY Change	-45.09%	8.45%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$97.41M	$100.2M	$96.14M
YoY Change	0.58%	4.21%	5.53%
Total Short-Term Liabilities	$136.8M	$140.7M	$127.0M
YoY Change	3.58%	10.76%	4.42%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$382.0K	$756.0K
YoY Change	-100.0%	-49.47%
Other Long-Term Liabilities	$5.197M	$5.469M	$4.851M
YoY Change	13.18%	12.74%	303.24%
Total Long-Term Liabilities	$5.197M	$5.851M	$5.607M
YoY Change	2.55%	4.35%	366.08%
TOTAL LIABILITIES
Total Short-Term Liabilities	$136.8M	$140.7M	$127.0M
Total Long-Term Liabilities	$5.197M	$5.851M	$5.607M
Total Liabilities	$142.0M	$146.5M	$132.6M
YoY Change	3.54%	10.49%	7.96%
SHAREHOLDERS EQUITY
Retained Earnings	-$348.2M	-$333.0M	-$327.3M
YoY Change	4.48%	1.75%	12.49%
Common Stock	$231.6M	$231.6M	$393.0K
YoY Change	0.0%	58842.24%	0.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$500.0K	$500.0K	$500.0K
YoY Change	0.0%	0.0%	0.0%
Treasury Stock Shares	134.8M shares	134.8M shares	$134.8M
Shareholders Equity	-$117.1M	-$101.9M	-$96.14M
YoY Change
Total Liabilities & Shareholders Equity	$24.87M	$44.68M	$36.50M
YoY Change	-28.85%	22.4%	-42.12%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q3
OPERATING ACTIVITIES
Net Income	-$15.22M	-$1.188M	-$1.852M
YoY Change	153.15%	-35.85%	-42.41%
Depreciation, Depletion And Amortization	$106.0K	$55.00K	$9.000K
YoY Change	-61.73%	511.11%	125.0%
Cash From Operating Activities	$3.380M	$1.938M	-$1.714M
YoY Change	-610.57%	-213.07%	-330.69%
INVESTING ACTIVITIES
Capital Expenditures	-$8.000K	-$12.00K	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$8.000K	-$12.00K	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.889M	-1.072M	2.133M
YoY Change	-1003.83%	-150.26%	-381.03%
NET CHANGE
Cash From Operating Activities	3.380M	1.938M	-1.714M
Cash From Investing Activities	-8.000K	-12.00K	0.000
Cash From Financing Activities	-1.889M	-1.072M	2.133M
Net Change In Cash	1.483M	854.0K	419.0K
YoY Change	-427.37%	103.82%	-2718.75%
FREE CASH FLOW
Cash From Operating Activities	$3.380M	$1.938M	-$1.714M
Capital Expenditures	-$8.000K	-$12.00K	$0.00
Free Cash Flow	$3.388M	$1.950M	-$1.714M
YoY Change	-611.78%	-213.77%	-330.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	City Area Code CityAreaCode	561
	dei	Entity Central Index Key EntityCentralIndexKey	0001590695
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Entity Address City Or Town EntityAddressCityOrTown	Boca Raton
	dei	Local Phone Number LocalPhoneNumber	443-4301
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
	dei	Trading Symbol TradingSymbol	TLCC
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	259092833	shares
CY2021Q3	us-gaap	Cash Cash	2148000	USD
CY2020Q4	us-gaap	Cash Cash	424000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	10399000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8425000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	10571000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	6301000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2067000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2195000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	25185000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	17345000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	143000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	65000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5847000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4710000	USD
CY2021Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2970000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3253000	USD
CY2021Q3	us-gaap	Goodwill Goodwill	8818000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	8818000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1713000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	760000	USD
CY2020Q4	us-gaap	Assets Assets	34951000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4612000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4712000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1003000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	742000	USD
CY2021Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	9661000	USD
CY2020Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	9372000	USD
CY2021Q3	us-gaap	Interest Payable Current InterestPayableCurrent	25233000	USD
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	20359000	USD
CY2021Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	100188000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	96847000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	140697000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	132032000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5469000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4592000	USD
CY2021Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	382000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	476000	USD
CY2021Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5851000	USD
CY2020Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5068000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	146548000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	137100000	USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000000	shares
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000000	shares
CY2021Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	393898884	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	392864182	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	394000	USD
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	393000	USD
CY2021Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	231249000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	231250000	USD
CY2021Q3	us-gaap	Common Stock Share Subscribed But Unissued Subscriptions Receivable CommonStockShareSubscribedButUnissuedSubscriptionsReceivable	30000	USD
CY2020Q4	us-gaap	Common Stock Share Subscribed But Unissued Subscriptions Receivable CommonStockShareSubscribedButUnissuedSubscriptionsReceivable	30000	USD
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	134806051	shares
CY2021Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	134806051	shares
CY2021Q3	us-gaap	Treasury Stock Value TreasuryStockValue	500000	USD
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	500000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-332985000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-333262000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-101872000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-102149000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	44676000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	34951000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	18272000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	18371000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	55841000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	47012000	USD
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	12230000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14669000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	37844000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	35322000	USD
CY2021Q3	us-gaap	Gross Profit GrossProfit	6042000	USD
CY2020Q3	us-gaap	Gross Profit GrossProfit	3702000	USD
	us-gaap	Gross Profit GrossProfit	17997000	USD
	us-gaap	Gross Profit GrossProfit	11690000	USD
CY2021Q3	us-gaap	Selling Expense SellingExpense	912000	USD
CY2020Q3	us-gaap	Selling Expense SellingExpense	420000	USD
	us-gaap	Selling Expense SellingExpense	2538000	USD
	us-gaap	Selling Expense SellingExpense	1044000	USD
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4096000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2981000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9067000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	1034000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	301000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	6392000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1921000	USD
CY2021Q3	us-gaap	Interest Expense InterestExpense	2208000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	2183000	USD
	us-gaap	Interest Expense InterestExpense	6619000	USD
	us-gaap	Interest Expense InterestExpense	6489000	USD
CY2021Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
CY2020Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	178000	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	35000	USD
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-14000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-148000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	504000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3000	USD
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2222000	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2153000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6115000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6457000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	-92924000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-87760000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1188000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1852000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	277000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1188000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-1852000	USD
	us-gaap	Net Income Loss NetIncomeLoss	277000	USD
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	259092833	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	258058131	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	258751722	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	257345636	shares
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	259086721	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	258751722	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	260486654	shares
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-1362000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	-94286000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-1852000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	-96138000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-102149000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	383000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-101766000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1188000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	-101872000	USD
	us-gaap	Net Income Loss NetIncomeLoss	277000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-8378000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	351000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	860000	USD
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	656000	USD
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	591000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	647000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	736000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	-1001000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	-206000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-682000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-3251000	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	USD
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	35000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1292000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3939000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3269000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1459000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-128000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	508000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	955000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	20000	USD
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	1344000	USD
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	6674000	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	0	USD
	us-gaap	Repayments Of Debt RepaymentsOfDebt	2310000	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	1257000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-56000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-99000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3443000	USD
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-655000	USD
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-599000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	5164000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	7289000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-730000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4408000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	147000	USD
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	671000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2601000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5035000	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	1724000	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	607000	USD
CY2020Q4	us-gaap	Cash Cash	424000	USD
CY2019Q4	us-gaap	Cash Cash	270000	USD
CY2021Q3	us-gaap	Cash Cash	2148000	USD
CY2020Q3	us-gaap	Cash Cash	877000	USD
	us-gaap	Interest Paid Net InterestPaidNet	1098000	USD
	us-gaap	Interest Paid Net InterestPaidNet	1032000	USD
	us-gaap	Nature Of Operations NatureOfOperations	<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-weight: bold;">Note </span><span style="font-family: 'Times New Roman'; font-weight: bold;"><span style="border-left: none; border-right: none;">1</span></span><span style="font-family: 'Times New Roman'; font-weight: bold;"> </span><span style="font-family: 'Times New Roman';">–</span><span style="font-family: 'Times New Roman'; font-weight: bold;"> Nature of Business </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Nature of Business</span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt; text-align: justify; font-size: 10pt;"><span style="font-family: 'Times New Roman';">Twinlab Consolidated Holdings, Inc. (the “Company”, “Twinlab,” “we,” “our” and “us”) was incorporated on </span><span style="font-family: 'Times New Roman';">October 24, 2013 </span><span style="font-family: 'Times New Roman';">under the laws of the State of Nevada as Mirror Me, Inc. On </span><span style="font-family: 'Times New Roman';">August 7, 2014, </span><span style="font-family: 'Times New Roman';">we amended our articles of incorporation and changed our name to Twinlab Consolidated Holdings, Inc.</span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt; text-align: justify; font-size: 10pt;"><span style="font-family: 'Times New Roman';">We are an integrated marketer, distributor, and retailer of branded nutritional supplements and other natural products sold to and through domestic health and natural food stores, mass market retailers, specialty store retailers, on-line retailers, and websites. Internationally, we market and distribute branded nutritional supplements and other natural products to and through health and natural product distributors and retailers.</span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt; text-align: justify; font-size: 10pt;"><span style="font-family: 'Times New Roman';">Our products include vitamins, minerals, specialty supplements and sports nutrition products sold under the Twinlab<span style="color: #000000; font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 36px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">®</span> brand name, a market leader in the healthy aging and beauty from within categories sold under the Reserveage Nutrition and ResVitale® brand names; diet and energy products sold under the Metabolife<span style="color: #000000; font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 36px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">®</span> brand name; and a full line of herbal teas sold under the Alvita<span style="color: #000000; font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 36px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important;">®</span> brand name. To accommodate consumer preferences, our products come in various formulations and delivery forms, including capsules, tablets, softgels, chewables, liquids, sprays and powders. These products are sold primarily through health and natural food stores and on-line retailers, supermarkets, and mass-market retailers.</span><span style="font-family: 'Times New Roman';"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt; text-align: justify; font-size: 10pt;"><span style="font-family: 'Times New Roman';">We also perform services between private label distributors and contract manufacturers under the NutraScience Labs (“NSL”) brand name. NSL facilitates the production of new supplements to market and reformulates existing products to include scientifically-backed ingredients. We provide our customers with numerous production services, including manufacturing, testing, label and packaging design, order fulfillment, and regulatory compliance.</span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt; text-align: justify; font-size: 10pt;"><span style="font-family: 'Times New Roman';">NSL facilitates the contract manufacture of a variety of high-quality vitamin and supplement products, including but </span><span style="font-family: 'Times New Roman';">not</span><span style="font-family: 'Times New Roman';"> limited to, immune support supplements, cognitive support products, prebiotics and probiotics, supplements for weight management, and sports nutrition supplements. Our role in the production of these products is to help our customers manufacture or reformulate dietary supplements for sale and distribution. We do this by working with contract manufacturers to build scientifically backed formulas for resale to our end customers. We also simplify the production process by providing quality control checks, storing inventory on site, labeling and designing finished products, and drop shipping finished products ready for sale to our end customers. We do </span><span style="font-family: 'Times New Roman';">not</span><span style="font-family: 'Times New Roman';"> market these private label products, but rather sell the products to the customer, who is then responsible for the marketing, distribution, and sale to retailers or to their end customers.</span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Going Concern</span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt; text-align: justify; font-size: 10pt;"><span style="font-family: 'Times New Roman';">The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which assumes continuity of operations and realization of assets and liabilities in the ordinary course of business. As of </span><span style="font-family: 'Times New Roman';">September 30, 2021, </span><span style="font-family: 'Times New Roman';">we had an accumulated deficit<span> of $</span></span><span><span style="font-family: 'Times New Roman';">332,985</span></span><span style="font-family: 'Times New Roman';">. Historical losses are primarily attributable to lower than planned sales resulting from low fill rates on demand due to limitations of our working capital, delayed product introductions and postponed marketing activities, merger-related and other restructuring costs, and interest and refinancing charges associated with our debt refinancing. Losses have been funded primarily through debt.</span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt; text-align: justify; font-size: 10pt;"><span style="font-family: 'Times New Roman';">Because of our history of operating losses and significant interest expense on our debt, we have a working capital deficiency of $</span><span style="font-family: 'Times New Roman';">115,512</span><span style="font-family: 'Times New Roman';"> as of </span><span style="font-family: 'Times New Roman';">September 30, 2021. </span><span style="font-family: 'Times New Roman';">We also have $</span><span style="font-family: 'Times New Roman';">100,188</span><span style="font-family: 'Times New Roman';"> of debt, net of discount, presented in current liabilities. These continuing conditions, among others, raise substantial doubt about our ability to continue as a going concern.</span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt; text-align: justify; font-size: 10pt;"><span style="font-family: 'Times New Roman';">Management has addressed operating issues through the following actions: focusing on growing the core business and brands; continuing emphasis on major customers and key products; reducing operating costs that include significant workforce and salary expense reduction and continuing to negotiate lower prices from major suppliers. </span><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';">We believe that we </span><span style="font-family: 'Times New Roman';">may </span><span style="font-family: 'Times New Roman';">need additional capital to execute our business plan. If additional funding is required, there can be </span><span style="font-family: 'Times New Roman';">no</span><span style="font-family: 'Times New Roman';"> assurance that sources of funding will be available when needed on acceptable terms or at all. To meet capital requirements, the Company </span><span style="font-family: 'Times New Roman';">may </span><span style="font-family: 'Times New Roman';">consider selling certain assets or seeking financing through a combination of equity offerings, debt financings, collaborations, strategic alliances, and licensing agreements.</span></p>
CY2021Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	100188000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Use of Estimates</span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'Times New Roman';"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt; text-align: justify; font-size: 10pt;"><span style="font-family: 'Times New Roman';">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Actual results could differ from those estimates. Significant management estimates include those with respect to returns and allowances, allowance for doubtful accounts, reserves for inventory obsolescence, the recoverability of long-lived assets, intangibles and goodwill and the estimated value of warrants and derivative liabilities.</span></p>
CY2021Q3	us-gaap	Contract With Customer Asset Accumulated Allowance For Credit Loss ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss	1419000	USD
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	536000	USD
CY2021Q3	tlcc	Contract With Customer Liability Customer Deposits Current ContractWithCustomerLiabilityCustomerDepositsCurrent	4604000	USD
CY2020Q4	tlcc	Contract With Customer Liability Customer Deposits Current ContractWithCustomerLiabilityCustomerDepositsCurrent	3874000	USD
CY2021Q3	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	56000	USD
CY2020Q4	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	60000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4660000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3934000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	18272000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	18371000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	47012000	USD
	us-gaap	Dilutive Securities DilutiveSecurities	-35000	USD
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1188000	USD
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	260486654	shares
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2020Q4	us-gaap	Contract With Customer Asset Accumulated Allowance For Credit Loss ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss	2101000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1127000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-1188000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-1852000	USD
	us-gaap	Net Income Loss NetIncomeLoss	277000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-8378000	USD
CY2021Q3	us-gaap	Dilutive Securities DilutiveSecurities	0	USD
CY2020Q3	us-gaap	Dilutive Securities DilutiveSecurities	-178000	USD
	us-gaap	Dilutive Securities DilutiveSecurities	0	USD
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-2030000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	277000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-8413000	USD
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	259092833	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	258058131	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	258751722	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	257345636	shares
CY2021Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2020Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	1028590	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	3141018	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	259092833	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	259086721	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	258751722	shares
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-style: italic;">Significant Concentration of Credit Risk</span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 6pt;"><span style="font-family: 'Times New Roman';"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; text-indent: 27pt; text-align: justify; font-size: 10pt; font-family: 'Times New Roman';"><span>Sales to our top three customers aggregated to approximately </span><span>24</span><span style="font-family: 'Times New Roman';">% and </span><span>27</span><span style="font-family: 'Times New Roman';">% of total sales for the </span><span style="border-left: none; border-right: none;">three months ended September 30, 2021</span><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';">and </span><span style="font-family: 'Times New Roman';">2020,</span><span style="font-family: 'Times New Roman';"> respectively, and </span><span>28</span><span style="font-family: 'Times New Roman';">% and </span><span>24</span><span style="font-family: 'Times New Roman';">% of total sales for the </span><span style="border-left: none; border-right: none;">nine months ended September 30, 2021</span><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';">and </span><span style="font-family: 'Times New Roman';">2020,</span><span style="font-family: 'Times New Roman';"> respectively. Sales to </span><span>one</span><span style="font-family: 'Times New Roman';"> of those customers were approximately </span><span>13</span><span style="font-family: 'Times New Roman';">% and </span><span>15</span><span style="font-family: 'Times New Roman';">% of total sales for the </span><span style="border-left: none; border-right: none;"><span style="border-right: none; border-left: none;">three months ended September 30, 2021</span></span><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';">and </span><span style="font-family: 'Times New Roman';">2020,</span><span style="font-family: 'Times New Roman';"> respectively, and </span><span>12</span><span style="font-family: 'Times New Roman';">% and </span><span>9</span><span style="font-family: 'Times New Roman';">% of total sales for the </span><span style="border-left: none; border-right: none;">nine months ended September 30, 2021</span><span style="font-family: 'Times New Roman';"> </span><span style="font-family: 'Times New Roman';">and </span><span style="font-family: 'Times New Roman';">2020,</span><span style="font-family: 'Times New Roman';"> respectively. Accounts receivable from the top </span><span>three</span><span style="font-family: 'Times New Roman';"> customers were approximately </span><span>35</span><span style="font-family: 'Times New Roman';">% and </span><span>21</span><span style="font-family: 'Times New Roman';">% </span><span style="font-size: 10pt; text-indent: 27pt; font-family: 'Times New Roman';">of total accounts receivable as of </span><span style="font-size: 10pt; text-indent: 27pt; font-family: 'Times New Roman';">September 30, 2021 </span><span style="font-size: 10pt; text-indent: 27pt; font-family: 'Times New Roman';">and </span><span style="font-size: 10pt; text-indent: 27pt; font-family: 'Times New Roman';">December 31, 2020, </span><span style="font-size: 10pt; text-indent: 27pt; font-family: 'Times New Roman';">respectively.</span><span style="font-size: 10pt; text-indent: 27pt; font-family: 'Times New Roman';"> </span><span style="font-size: 10pt; text-indent: 27pt; font-family: 'Times New Roman';"> A single customer represents </span><span>5</span><span style="font-size: 10pt; text-indent: 27pt; font-family: 'Times New Roman';">% and </span><span>10</span><span style="font-size: 10pt; text-indent: 27pt; font-family: 'Times New Roman';">% of total accounts receivable as of </span><span style="font-size: 10pt; text-indent: 27pt; font-family: 'Times New Roman';">September 30, 2021 </span><span style="font-size: 10pt; text-indent: 27pt; font-family: 'Times New Roman';">and </span><span style="font-size: 10pt; text-indent: 27pt; font-family: 'Times New Roman';">December 31, 2020</span><span style="font-size: 10pt; text-indent: 27pt; font-family: 'Times New Roman';">, </span><span style="font-size: 10pt; text-indent: 27pt; font-family: 'Times New Roman';">respectively. This customer is a related party through a director who sits on both the Company’s Board of Directors and that of the customer.</span></p>
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1746000	USD
CY2021Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	5745000	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2053000	USD
CY2021Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5571000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5994000	USD
CY2021Q3	us-gaap	Inventory Gross InventoryGross	11316000	USD
CY2020Q4	us-gaap	Inventory Gross InventoryGross	8047000	USD
CY2021Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	745000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	10571000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	6301000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	291000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	144000	USD
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	148000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	79000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	143000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	65000	USD
CY2021Q3	us-gaap	Depreciation Depreciation	55000	USD
CY2020Q3	us-gaap	Depreciation Depreciation	9000	USD
	us-gaap	Depreciation Depreciation	69000	USD
	us-gaap	Depreciation Depreciation	28000	USD
CY2021Q3	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1400000	USD
CY2020Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1400000	USD
CY2021Q3	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	13522000	USD
CY2021Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	10552000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	10269000	USD
CY2021Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2970000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3253000	USD
CY2021Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	94000	USD
CY2020Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	277000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	283000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	832000	USD
CY2021Q3	us-gaap	Long Term Debt LongTermDebt	100570000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	97323000	USD
CY2021Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	100188000	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	96847000	USD
CY2021Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	382000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	476000	USD
CY2020Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.07
CY2020Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	6034702	shares
	tlcc	Class Of Warrant Or Right Granted During Period Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightGrantedDuringPeriodNumberOfSecuritiesCalledByWarrantsOrRights	0	shares
	tlcc	Class Of Warrant Or Right Granted During Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightGrantedDuringPeriodExercisePriceOfWarrantsOrRights	0
	tlcc	Class Of Warrant Or Right Cancelled During Period Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightCancelledDuringPeriodNumberOfSecuritiesCalledByWarrantsOrRights	500000	shares
	tlcc	Class Of Warrant Or Right Canceled During Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightCanceledDuringPeriodExercisePriceOfWarrantsOrRights	0
	tlcc	Class Of Warrant Or Right Exercised During Period Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightExercisedDuringPeriodNumberOfSecuritiesCalledByWarrantsOrRights	1034702	shares
	tlcc	Class Of Warrant Or Right Exercised During Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisedDuringPeriodExercisePriceOfWarrantsOrRights	0
CY2021Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	4500000	shares
CY2021Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
CY2021Q3	us-gaap	Lease Cost LeaseCost	244000	USD
	us-gaap	Lease Cost LeaseCost	675000	USD
CY2021Q3	us-gaap	Variable Lease Cost VariableLeaseCost	81000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	244000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	366000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1505000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1534000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1524000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1566000	USD
CY2021Q3	tlcc	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	1455000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	7950000	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1478000	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	6472000	USD
CY2021Q3	us-gaap	Sublease Income SubleaseIncome	196000	USD
	us-gaap	Sublease Income SubleaseIncome	582000	USD
CY2021Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	355000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	1013000	USD
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y1M6D
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y1M6D
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0825	pure
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0825	pure
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000000	shares
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	7194412	shares
CY2021Q3	us-gaap	Common Stock Share Subscribed But Unissued Subscriptions Receivable CommonStockShareSubscribedButUnissuedSubscriptionsReceivable	30000	USD
CY2021Q3	tlcc	Subscription Receivable Annual Interest Rate SubscriptionReceivableAnnualInterestRate	0.05	pure

Files In Submission

Name	View Source	Status
0001753926-21-000710-index-headers.html	Edgar Link	pending
0001753926-21-000710-index.html	Edgar Link	pending
0001753926-21-000710.txt	Edgar Link	pending
0001753926-21-000710-xbrl.zip	Edgar Link	pending
ex311_1.htm	Edgar Link	pending
ex312_2.htm	Edgar Link	pending
ex321_3.htm	Edgar Link	pending
ex322_4.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tlcc-20210930.htm	Edgar Link	pending
tlcc-20210930.xsd	Edgar Link	pending
tlcc-20210930_cal.xml	Edgar Link	unprocessable
tlcc-20210930_def.xml	Edgar Link	unprocessable
tlcc-20210930_htm.xml	Edgar Link	completed
tlcc-20210930_lab.xml	Edgar Link	unprocessable
tlcc-20210930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TLCC
Twinlab Consolidated Holdings Inc Stock $tlcc

2021 Q4 Form 10-Q Financial Statement

#000175392621000710 Filed on November 15, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TLCC Twinlab Consolidated Holdings Inc Stock $tlcc

2021 Q4 Form 10-Q Financial Statement

#000175392621000710 Filed on November 15, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TLCC
Twinlab Consolidated Holdings Inc Stock $tlcc